Quantum Genomics SA (ALQGC):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Quantum Genomics SA (ALQGC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C7587)・商品コード:DATA904C7587
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:50
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,750見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Quantum Genomics SA (Quantum Genomics) is a biopharmaceutical company which develops novel medicines in the field of cardiovascular diseases. The company develops drugs to treat high blood pressure and heart failure. Its research programs are based on the Brain Aminopeptidase A Inhibition (BAPAI), a real triple action innovative therapeutic platform. Quantum Genomics BAPAI products pipeline include QGC001 for the treatment of high blood pressure with monotherapy drug; and QGC011 for the treatment of hypertension through combination therapy in pre-clinical phase. The company offers QGC006 for the optimization of the treatment of hypertension with a monotherapy drug; and QGC101 for the prevention and treatment of heart failure. The company partners with biotech research entities, academic teams, and pharmaceutical and bio-science companies to develop new drugs. QGS is headquartered in Paris, France.

Quantum Genomics SA (ALQGC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Quantum Genomics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Quantum Genomics SA, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Quantum Genomics Enters into Research Agreement with University of Ottawa Heart Institute and Center for Interdisciplinary Research in Biology 11
Quantum Genomics Enters into Co-Development Agreement for QGC101 12
Equity Offering 13
Quantum Genomics to Raise USD7.4 Million in First Tranche of Private Placement of Shares 13
Quantum Genomics Raises USD9.6 Million in Private Placement of Shares 14
Quantum Genomics Raises USD3.4 Million in Public Offering of Shares 15
Quantum Genomics Raises USD6 Million in Private Placement of Shares 16
Quantum Genomics Completes Underwriters Exercise of Over-Allotment Option of IPO for USD14.4 Million 17
Quantum Genomics Raises Additional USD0.33 Million in Private Placement of Shares 19
Quantum Genomics Raises USD4.7 Million in Private Placement of Shares 20
Debt Offering 21
Quantum Genomics Raises USD3.7 Million in Public Offering of Bonds 21
Quantum Genomics SA – Key Competitors 22
Quantum Genomics SA – Key Employees 23
Quantum Genomics SA – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Strategy And Business Planning 25
Apr 19, 2018: Quantum Genomics enters a new phase of maturity with its BAPAIs Fast Growth strategic plan 25
Financial Announcements 28
Mar 29, 2018: Quantum Genomics publishes its financial results for the year 2017 28
Oct 03, 2017: Quantum Genomics Releases 2017 First-Half Financial Results and First Nine Months Business Update 30
Mar 30, 2017: Quantum Genomics: 2016 annual financial results 32
Corporate Communications 34
Apr 09, 2018: Quantum Genomics strengthens its governance 34
Feb 05, 2018: Quantum Genomics strengthens its Scientific Advisory Board with the appointment of Professor Frans Leenen, a renowned expert in congestive heart failure 35
Jul 11, 2017: Quantum Genomics begins trading in the U.S. on OTCQX 36
Jun 30, 2017: Quantum Genomics appoints Professor Toshiro Fujita as member of its Scientific Advisory Board 37
Apr 25, 2017: Quantum Genomics appoints Bruno Besse as Chief Medical Officer 38
Product News 39
10/27/2017: Quantum Genomics receives the Galien MedStartUp award for the innovative design of its NEW-HOPE study 39
10/16/2017: Quantum Genomics nominated for the Galien MedStartUp Award for the innovative design of its NEW-HOPE trial 40
06/04/2018: FIRIBASTAT Approved as Common International Name for QGC001 by World Health Organization 41
Clinical Trials 42
Nov 15, 2017: Quantum Genomics announces recruitment of first patients in the NEW-HOPE arterial hypertension study in the United States 42
Sep 05, 2017: Quantum Genomics Receives FDA Clearance of IND Application for QGC001 43
Jun 28, 2017: Quantum Genomics announces the design of its next Phase II trial in arterial hypertension, NEW-HOPE 44
Jun 19, 2017: Quantum Genomics details positive results from its Phase IIa trial of QGC001 for the treatment of arterial hypertension 46
May 09, 2017: Quantum Genomics will organize a teleconference on June 19, 2017, to comment on phase IIa data in high blood pressure 48
Mar 14, 2017: Quantum Genomics announces positive data from new preclinical studies with QGC001 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
Quantum Genomics SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Quantum Genomics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Quantum Genomics SA, Deals By Therapy Area, 2012 to YTD 2018 9
Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Quantum Genomics Enters into Research Agreement with University of Ottawa Heart Institute and Center for Interdisciplinary Research in Biology 11
Quantum Genomics Enters into Co-Development Agreement for QGC101 12
Quantum Genomics to Raise USD7.4 Million in First Tranche of Private Placement of Shares 13
Quantum Genomics Raises USD9.6 Million in Private Placement of Shares 14
Quantum Genomics Raises USD3.4 Million in Public Offering of Shares 15
Quantum Genomics Raises USD6 Million in Private Placement of Shares 16
Quantum Genomics Completes Underwriters Exercise of Over-Allotment Option of IPO for USD14.4 Million 17
Quantum Genomics Raises Additional USD0.33 Million in Private Placement of Shares 19
Quantum Genomics Raises USD4.7 Million in Private Placement of Shares 20
Quantum Genomics Raises USD3.7 Million in Public Offering of Bonds 21
Quantum Genomics SA, Key Competitors 22
Quantum Genomics SA, Key Employees 23

List of Figures
Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★調査レポート[Quantum Genomics SA (ALQGC):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C7587)販売に関する免責事項を必ずご確認ください。
★調査レポート[Quantum Genomics SA (ALQGC):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆